Literature DB >> 19230857

OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis.

P Ornetti1, K Brandt, M-P Hellio-Le Graverand, M Hochberg, D J Hunter, M Kloppenburg, N Lane, J-F Maillefert, S A Mazzuca, T Spector, G Utard-Wlerick, E Vignon, M Dougados.   

Abstract

BACKGROUND: Joint space width (JSW) evaluated in millimeters on plain X-rays is the currently optimal recognized technique to evaluate osteoarthritis (OA) structural progression. Data obtained can be presented at the group level (e.g., mean+/-standard deviation of the changes). Such presentation makes difficult the interpretation of the clinical relevance of the reported results. Therefore, a presentation at the individual level (e.g., % progressors) seems more attractive but requires to determining a cut-off. Several methodologies have been proposed to define cut-offs in JSW: arbitrary chosen cut-off, cut-off based on the validity to predict a relevant end-point such as the requirement of total articular replacement or cut-off based on the measurement error such as smallest detectable difference (SDD).
OBJECTIVES: The objective of this OARSI-OMERACT initiative was to define a cut-off evaluated in millimeters on plain X-rays above which a change in JSW could be considered as relevant in patients with hip and knee OA.
METHODS: The first step consisted in a systematic literature research performed using Medline database up to July 2007 to obtain all manuscripts published between 1990 and 2007 reporting a cut-off value in JSW evaluated in millimeters at either the knee or hip level. The second step consisted in a consensus based on the best knowledge of the 11 experts with the support of the available evidence.
RESULTS: Among the 506 articles selected by the search, 47 articles reported cut-off of JSW in millimeters. There was a broad heterogeneity in cut-off values, whatever the methodologies or the OA localization considered (e.g., from 0.12 to 0.84 mm and from 0.22 to 0.78 mm for Knee (seven studies) and hip (seven studies), respectively when considering the data obtained based on the reliability). Based on the data extracted in the literature, the expert committee proposed a definition of relevant change in JSW based on plain X-rays, on an absolute change of JSW in millimeters and on the measurement error e.g., calculation of the SDD using the Bland and Altman technique. The results of the analysis of JSW should be expressed in terms of a dichotomous variable (e.g., progressors yes/no): a patient with a change in JSW during the study over such SDD will fulfill the definition of "progressor". Moreover, the pilot study aimed at evaluating the measurement error should be designed to reflect the different characteristics of the primary study in which the analysis of the radiological findings will be based on (patient's characteristics, centers characteristics, readers).
CONCLUSION: This initiative based on both an Evidence Based Medicine (Systematic Literature Research) and Expert Opinion approach resulted in a proposal of definition of relevant radiological progression in OA to be used as end-point in clinical trials and also recommendations on the conduct of the reliability study allowing such definition.

Entities:  

Mesh:

Year:  2009        PMID: 19230857      PMCID: PMC6869332          DOI: 10.1016/j.joca.2009.01.007

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  49 in total

1.  Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views.

Authors:  J C Buckland-Wright; F Wolfe; R J Ward; N Flowers; C Hayne
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

2.  Relevant change in radiological progression in patients with hip osteoarthritis. II. Determination using an expert opinion approach.

Authors:  J F Maillefert; M Nguyen; A Gueguen; L Berdah; M Lequesne; B Mazières; E Vignon; M Dougados
Journal:  Rheumatology (Oxford)       Date:  2002-02       Impact factor: 7.580

3.  X-ray technologists' reproducibility from automated measurements of the medial tibiofemoral joint space width in knee osteoarthritis for a multicenter, multinational clinical trial.

Authors:  J Chris Buckland-Wright; Charles F Bird; Cathy A Ritter-Hrncirik; Gary A Cline; Carol Tonkin; Thomas N Hangartner; Rupert J Ward; Joan M Meyer; Michael P Meredith
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

4.  Quantitative assessment of joint space width with an electronic caliper.

Authors:  P Hilliquin; E Pessis; J Coste section sign; D Mauget; A Azria; A Chevrot; C-J Menkès; A Kahan
Journal:  Osteoarthritis Cartilage       Date:  2002-07       Impact factor: 6.576

5.  Concomitant therapy: an outcome variable for musculoskeletal disorders? Part 2: total joint replacement in osteoarthritis trials.

Authors:  Jean-Francis Maillefert; Gillian A Hawker; Laure Gossec; Nizar N Mahomed; Stefan Lohmander; Paul A Dieppe; Gustavo Zanoli; Marc C Hochberg; Maxime Dougados
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

6.  Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis.

Authors:  P Ravaud; B Giraudeau; G R Auleley; J L Drape; B Rousselin; L Paolozzi; C Chastang; M Dougados
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

7.  Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees.

Authors:  J C Buckland-Wright; D G Macfarlane; S A Williams; R J Ward
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

8.  Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis.

Authors:  X Chevalier; T Conrozier; M Gehrmann; P Claudepierre; P Mathieu; S Unger; E Vignon
Journal:  Osteoarthritis Cartilage       Date:  2001-05       Impact factor: 6.576

9.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

10.  Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip.

Authors:  M Dougados; M Nguyen; L Berdah; B Maziéres; E Vignon; M Lequesne
Journal:  Arthritis Rheum       Date:  2001-11
View more
  45 in total

1.  Effects of prescription nonsteroidal antiinflammatory drugs on symptoms and disease progression among patients with knee osteoarthritis.

Authors:  Kate L Lapane; Shibing Yang; Jeffrey B Driban; Shao-Hsien Liu; Catherine E Dubé; Timothy E McAlindon; Charles B Eaton
Journal:  Arthritis Rheumatol       Date:  2015-03       Impact factor: 10.995

Review 2.  Pharmacologic therapy for osteoarthritis--the era of disease modification.

Authors:  David J Hunter
Journal:  Nat Rev Rheumatol       Date:  2010-11-16       Impact factor: 20.543

3.  Brief Report: Cartilage Thickness Change as an Imaging Biomarker of Knee Osteoarthritis Progression: Data From the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium.

Authors:  F Eckstein; J E Collins; M C Nevitt; J A Lynch; V B Kraus; J N Katz; E Losina; W Wirth; A Guermazi; F W Roemer; D J Hunter
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

4.  The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement.

Authors:  L Gossec; S Paternotte; J F Maillefert; C Combescure; P G Conaghan; A M Davis; K-P Gunther; G Hawker; M Hochberg; J N Katz; M Kloppenburg; K Lim; L S Lohmander; N N Mahomed; L March; K Pavelka; L Punzi; E M Roos; L Sanchez-Riera; J A Singh; M E Suarez-Almazor; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2010-10-31       Impact factor: 6.576

5.  Longitudinal association between foot and ankle symptoms and worsening of symptomatic radiographic knee osteoarthritis: data from the osteoarthritis initiative.

Authors:  K L Paterson; J Kasza; D J Hunter; R S Hinman; H B Menz; G Peat; K L Bennell
Journal:  Osteoarthritis Cartilage       Date:  2017-05-13       Impact factor: 6.576

6.  Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the Intensive Diet and Exercise for Arthritis trial (IDEA).

Authors:  R F Loeser; D P Beavers; A C Bay-Jensen; M A Karsdal; B J Nicklas; A Guermazi; D J Hunter; S P Messier
Journal:  Osteoarthritis Cartilage       Date:  2017-07-27       Impact factor: 6.576

7.  The relationship between smoking and knee osteoarthritis in the Osteoarthritis Initiative.

Authors:  C E Dubé; S-H Liu; J B Driban; T E McAlindon; C B Eaton; K L Lapane
Journal:  Osteoarthritis Cartilage       Date:  2015-10-17       Impact factor: 6.576

8.  T1ρ and T2 relaxation times are associated with progression of hip osteoarthritis.

Authors:  M C Gallo; C Wyatt; V Pedoia; D Kumar; S Lee; L Nardo; T M Link; R B Souza; S Majumdar
Journal:  Osteoarthritis Cartilage       Date:  2016-03-10       Impact factor: 6.576

9.  Baseline and longitudinal change in isometric muscle strength prior to radiographic progression in osteoarthritic and pre-osteoarthritic knees--data from the Osteoarthritis Initiative.

Authors:  F Eckstein; W Hitzl; J Duryea; C Kent Kwoh; W Wirth
Journal:  Osteoarthritis Cartilage       Date:  2013-03-06       Impact factor: 6.576

10.  Sample size for prospective studies of hip joint space width narrowing in osteoarthritis by the use of radiographs.

Authors:  Petri Sipola; Lea H Niemitukia; Mika M Hyttinen; Jari P A Arokoski
Journal:  Skeletal Radiol       Date:  2010-08-26       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.